Tagged with Gene therapy

China William Wei Cao, chairman and CEO of Gracell, shares the fascinating journey that inspired him to establish Gracell in Shanghai to tackle the four big challenges facing the global CAR-T industry; the four novel technology platforms Gracell is working on that are already drawing significant investor and Big Pharma interest;…

France André Choulika, Chairman and CEO of Cellectis, discusses how UCART will revolutionize cell therapy as a universal gene-edited solution as opposed to the current therapies on the market which uses a patient’s own re-engineered T-cells. Choulika goes on to share how the company is positioning itself for its anticipated commercialization…

Korea Cure Therapeutics is a startup developing gene and cell therapies in Korea. Its founder David Kim explains where his passion for regenerative therapies stems from, breaks down the main hurdles standing in the way of success and describes how his company’s business model focused on flexibility and development speed through…

Opinion Kamala Maddali, vice president for Biopharma Collaborations & Companion Diagnostics at Cancer Genetics, discusses what impact next generation sequencing (NGS) stands to have on cancers that affect women.   NGS technology allows for the rapid and accurate sequencing of many genes at once 2018 saw an estimated 18 million cancer…

China China is planning to establish a new national medical ethics committee in the wake of the “CRISPR babies” scandal.   The committee will not be limited to overseeing gene editing alone, but also cover cloning, cell therapy, xenotransplantation, mitochondrial replacement, and nanotechnology The new body, according to reports, will oversee…

Korea Woosok Lee, CEO of Kolon Pharma, Kolon Life Science and Kolon TissueGene, offers his insights into the potential of their blockbuster product Invossa which could exceed USD five billion of revenues in the USA following its approval. Mr Lee also clarifies Korea’s position within gene therapy R&D and explains Kolon’s…

Korea Kyoung-June Lee, CEO of JW CreaGene, lifts the lid on their novel technology of developing an immuno-oncology treatment from dendritic cells, which act as a command centre of the immune system in the body. He also assesses how this new treatment will compare to existing technologies, such as CAR-T.  …

Korea Dr BG Rhee, CEO of SCM Lifescience discusses their patented proprietary subfraction technology to extract high purity cell cultures, and the impact this will have on the efficacy, cell differentiation ability, and cost of stem cell treatments. Dr Rhee also provides his assessment of the regulatory framework for stem cells…

Korea Sunyoung Kim, CEO and founder of ViroMed, reveals his strategy for conquering the US market and the feasibility of his ambitions for ViroMed to become the biotech company with the largest revenues from gene therapy by 2025. He also discusses the areas within the Korean biotech sphere that must develop…

France Genethon, a laboratory created by the patient organization AFM-Telethon, is one of the world’s leaders in the development of biotherapies for rare diseases. In this interview Genethon’s CEO Frédéric Revah explains its role in the discovery of innovative therapies since the 1990s and the recent launch of YposKesi, its innovative…

UK A spinout from the Roslin Institute that created Dolly the Sheep, Roslin CT is a cell and gene therapy CDMO, with a unique positioning in the field today. Its CEO, Janet Downie, presents the company’s expansion plans and talks about new areas worth pursuing as well as the advantages of…

Cancer Novartis receives NHS approval for their CAR T-cell therapy to treat leukaemia in children, 10 days after receiving European Commission (EC) approval. “It’s fantastic news for children and young people with this form of leukaemia.” Prof Charles Swanton, Cancer Research UK’s Dubbed as the future of cancer therapy, Kymriah, Novartis’ gene-modifying treatment…